Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
In short, CEOs can't be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.
I'm not suggesting that colleges become vocational schools. But don't you think they should also help young people prepare for the life they're going to be living?
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.
Until now, your superiors have promoted you. Now it's your responsibility to show why you belong.
Why would any CEO tolerate a corporate culture that holds people back?
When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.
If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.
- Why President Trump Won't Overhaul the FDA
- Five things for pharma marketers to know: Monday, February 27, 2017
- Guidemark Health's Sophy Regelous on why small budgets are increasing
- What uncertainty? 72% of health marketers say 2017 budgets are up
- Publicis Health formalizes new name, promotes 3 execs